Potential prognostic value of HER2/CEP17 FISH ratio in HER2-positive non-metastatic breast cancer: a real-world study

被引：0

作者：

Fangchao Zheng ^{[1
]}

Feng Du ^{[2
]}

Zixuan Yang ^{[3
]}

Xue Wang ^{[1
]}

Jian Yue ^{[1
]}

Yun Ling ^{[1
]}

Peng Yuan ^{[4
]}

机构：

[1] Chinese Academy of Medical Sciences and Peking Union Medical College,Department of VIP Medical Services, Department of Medical Oncology, National Cancer Centre/National Clinical Research Center for Cancer/Cancer Hospital

[2] Shandong First Medical University and Shandong Academy of Medical Sciences,Department of Medical Oncology, Cancer Research Center, Shandong Cancer Hospital and Institute

[3] Peking University Cancer Hospital and Institute,Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), The VIPII Gastrointestinal Cancer Division of Medical Department

[4] Chinese Academy of Medical Sciences and Peking Union Medical College,Department of Pathology, National Cancer Centre/National Clinical Research Center for Cancer/Cancer Hospital

来源：

Discover Oncology | / 16卷 / 1期

关键词：

Breast cancer; HER2; HER2/CEP17 ratio; Prognosis; Trastuzumab;

D O I：

10.1007/s12672-025-02495-2

中图分类号：

学科分类号：

摘要：

The HER2/CEP17 ratio cannot be used as a marker to predict DFS and OS in non-metastatic HER2-positive BC patients in a mixed population of patients, some of whom received trastuzumab and others of whom did notA higher HER2/CEP17 ratio was associated with a worse DFS in patients with non-metastatic HER2-positive breast cancer patients receiving trastuzumab.The HER2/CEP17 ratio may be considered a potential biomarker to predict prognosis in patients with non-metastatic HER2-positive breast cancer receiving trastuzumab.

引用